Markers of cell proliferation, apoptosis, and angiogenesis in thyroid adenomas: A comparative immunohistochemical and genetic investigation of functioning and nonfunctioning nodules

Thyroid

Volumn 17, Issue 3, 2007, Pages 191-197

  Viacava, Paolo ^a   Bocci, Guido ^a   Tonacchera, Massimo ^a   Fanelli, Giovanni ^a   DeServi, Melissa ^a   Agretti, Patrizia ^a   Berti, Edoardo ^a   Goletti, Orlando ^b   Aretini, Paolo ^a   Resta, Maria Letizia ^c   Bevilacqua, Generoso ^a   Naccarato, Antonio Giuseppe ^a  

^a UNIVERSITY OF PISA   (Italy)

^b General Hospital   (Italy)

^c UNIVERSITY OF MESSINA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; GALECTIN 3; GUANINE NUCLEOTIDE BINDING PROTEIN ALPHA SUBUNIT; KI 67 ANTIGEN; LEVOTHYROXINE; PROTEIN BCL 2; PROTEIN P53; RAS PROTEIN; STIMULATORY GUANINE NUCLEOTIDE BINDING PROTEIN; THIAMAZOLE; THYROTROPIN RECEPTOR; VASCULOTROPIN A;

ANGIOGENESIS; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CLINICAL ARTICLE; GENE EXPRESSION; GENE MUTATION; GENETIC ANALYSIS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MICROVASCULATURE; ONCOGENE H RAS; ONCOGENE K RAS; ONCOGENE N RAS; ONCOGENE RAS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SUBTOTAL THYROIDECTOMY; THYROID ADENOMA; THYROID NODULE;

ADENOMA; ANTIGENS, CD34; APOPTOSIS; CELL PROLIFERATION; HUMANS; IMMUNOHISTOCHEMISTRY; NEOVASCULARIZATION, PATHOLOGIC; PROTO-ONCOGENE PROTEINS C-BCL-2; SEQUENCE ANALYSIS, DNA; THYROID NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 34147105999     PISSN: 10507256     EISSN: None     Source Type: Journal    
DOI: 10.1089/thy.2006.0175     Document Type: Article

References (32)

1. Welker MJ, Orlov D 2003 Thyroid nodules. Am Fam Physician 67:559-566.
2. Zeiger MA, Dackiw AP 2005 Follicular thyroid lesions, elements that affect both diagnosis and prognosis. J Surg Oncol 89:108-113.
3. Weber AL, Randolph G, Aksoy FG 2000 The thyroid and parathyroid glands. CT and MR imaging and correlation with pathology and clinical findings. Radiol Clin North Am 38:1105-1129.
4. Tonacchera M, Vitti P, Agretti P, Ceccarini G, Perri A, Cavaliere R, Mazzi B, Naccarato AG, Viacava P, Miccoli P, Pinchera A, Chiovato L 1999 Functioning and nonfunctioning thyroid adenomas involve different molecular pathogenetic mechanisms. J Clin Endocrinol Metab 84:4155-4161.
5. Gozu H, Avsar M, Bircan R, Claus M, Sahin S, Sezgin O, Deyneli O, Paschke R, Cirakoglu B, Akalin S 2005 Two novel mutations in the sixth transmembrane segment of the thyrotropin receptor gene causing hyperfunctioning thyroid nodules. Thyroid 15:389-397.
6. Voigt C, Holzapfel HP, Meyer S, Paschke R 2004 Increased expression of G-protein-coupled receptor kinases 3 and 4 in hyperfunctioning thyroid nodules. J Endocrinol 182:173-182.
7. Trulzsch B, Krohn K, Wonerow P, Chey S, Holzapfel HP, Ackermann F, Fuhrer D, Paschke R 2001 Detection of thyroid-stimulating hormone receptor and Gsalpha mutations: in 75 toxic thyroid nodules by denaturing gradient gel electrophoresis. J Mol Med 78:684-691.
8. Krohn K, Reske A, Ackermann F, Muller A, Paschke R 2001 Ras mutations are rare in solitary cold and toxic thyroid nodules. Clin Endocrinol 55:241-248.
9. Krohn K, Paschke R 2004 BRAF mutations are not an alternative explanation for the molecular etiology of ras-mutation negative cold thyroid nodules. Thyroid 14:359-361.
10. Urruticoechea A, Smith IE, Dowsett M 2005 Proliferation marker Ki-67 in early breast cancer. J Clin Oncol 23:7212-7220.
11. Saiz AD, Olvera M, Rezk S, Florentine BA, McCourty A, Brynes RK 2002 Immunohistochemical expression of cyclin D1, E2F-1, and Ki-67 in benign and malignant thyroid lesions. J Pathol 198:157-162.
12. Spyratos F, Ferrero-Pous M, Trassard M, Hacene K, Phillips E, Tubiana-Hulin M, Le Doussal V 2002 Correlation between MIB-1 and other proliferation markers: clinical implications of the MIB-1 cutoff value. Cancer 94:2151-2159.
13. Kim R 2005 Unknotting the roles of Bcl-2 and Bcl-xL in cell death. Biochem Biophys Res Commun 333:336-343.
14. Gomez-Lazaro M, Fernandez-Gomez FJ, Jordan J 2004 p53: twenty-five years understanding the mechanism of genome protection. J Physiol Biochem 60:287-307.
15. Puglisi F, Cesselli D, Damante G, Pellizzari L, Beltrami CA, Di Loreto C 2000 Expression of Pax-8, p53 and bcl-2 in human benign and malignant thyroid diseases. Anticancer Res 20:311-316.
16. Nasir A, Catalano E, Calafati S, Cantor A, Kaiser HE, Coppola D 2004 Role of p53, CD44V6 and CD57 in differentiating between benign and malignant follicular neoplasms of the thyroid. In Vivo 18:189-195.
17. Lanza F, Healy L, Sutherland DR 2001 Structural and functional features of the CD34 antigen: an update. J Biol Regul Homeost Agents 15:1-13.
18. Rzeszutko M, Rzeszutko W, Dziegiel P 2004 The morphological analysis of vasculature in thyroid tumours: immunoexpression of CD34 antigen. Folia Histochem Cytobiol 42:235-240.
19. Ferrara N 2005 The role of VEGF in the regulation of physiological and pathological angiogenesis. EXS 94:209-231.
20. Turner HE, Harris AL, Melmed S, Wass JA 2003 Angiogenesis in endocrine tumors. Endocr Rev 24:600-632.
21. Huang SM, Lee JC, Wu TJ, Chow NH 2001 Clinical relevance of vascular endothelial growth factor for thyroid neoplasms. World J Surg 25:302-306.
22. Gasbarri A, Marchetti C, Iervasi G, Bottoni A, Nicolini A, Bartolazzi A, Carpi A 2004 From the bench to the bedside. Galectin-3 immunodetection for improving the preoperative diagnosis of the follicular thyroid nodules. Biomed Pharmacother 58:356-359.
23. Bartolazzi A, Gasbarri A, Papotti M, Bussolati G, Lucante T, Kahan A, Inohara H, Marandino F, Orlandi F, Nardi F, Vecchione A, Tecce R, Larsson O, the Thyroid Cancer Study Group 2001 Application of an immunodiagnostic method for improving preoperative diagnosis of nodular thyroid lesions. Lancet 357:1644-1650.
24. Carpi A, Naccarato AG, Iervasi G, Nicolini A, Bevilacqua G, Viacava P, Collecchi P, Lavra L, Marchetti C, Sciacchitano S, Bartolazzi A 2006 Large needle aspiration biopsy and galectin-3 determination in selected thyroid nodules with indeterminate FNA-cytology. Br J Cancer 95:204-209.
25. Tonacchera M, Chiovato L, Pinchera A, Agretti P, Fiore E, Cetani F, Rocchi R, Viacava P, Miccoli P, Vitti P 1998 Hyperfunctioning thyroid nodules in toxic multinodular goiter share activating in thyrotropin receptor mutations with solitary toxic adenoma. J Clin Endocrinol Metab 83: 492-498.
26. Vasko V, Ferrand M, Di Cristofaro J, Carayon P, Henry JF, de Micco C 2003 Specific pattern of RAS oncogene mutations in follicular thyroid tumors. J Clin Endocrinol Metab 88:2745-2752.
27. Raymond M, Rousset F 1995 An exact test for population differentiation. Evolution 49:1280-1283.
28. Deleu S, Allory Y, Radulescu A, Pirson I, Carrasco N, Corvilain B, Salmon I, Franc B, Dumont JE, Van Sande J, Maenhaut C 2000 Characterization of autonomous thyroid adenoma: metabolism, gene expression, and pathology. Thyroid 10:131-140.
29. Mazeto GM, Oliveira ML, Padovani CR, Montenegro MR, Aragon FF, Schmitt FC 2004 Thyroid cell proliferation in Graves' disease. Use of MIB-1 monoclonal antibody. Acta Cytol 48:57-63.
30. Segal K, Shpitzer T, Feinmesser M, Stern Y, Feinmesser R 1996 Angiogenesis in follicular tumors of the thyroid. J Surg Oncol 63:95-98.
31. Goldenberg JD, Portugal LG, Wenig BL, Ferrer K, Wu JC, Sabnani J 1998 Well differentiated thyroid carcinomas: p53 mutation status and microvessel density. Head Neck 20:152-158.
32. Herrmann G, Schumm-Draeger PM, Muller C, Atai E, Wenzel B, Fabian T, Usadel KH, Hubner K 1994 T lymphocytes, CD68-positive cells and vascularisation in thyroid carcinomas. J Cancer Res Clin Oncol 120:651-656.